Karachi: GlaxoSmithKline Pakistan Limited convened a board meeting on July 30, 2024, to deliberate on various issues not related to the company's financial results. This assembly did not result in the release of any market-sensitive data that could influence the company's share price.

The gathering of GlaxoSmithKline Pakistan Limited's Board of Directors was significant as it focused on matters beyond the typical financial disclosures, underscoring a broader agenda. Despite the discussions, the company confirmed that there was no dissemination of any information deemed sensitive to stock prices. As per regulatory requirements, the details of the meeting have been communicated to certificate holders of the Pakistan Stock Exchange (PSX).

According to information available from the Pakistan Stock Exchange (PSX), this disclosure aligns with the corporate governance norms ensuring transparency in operations without adversely impacting market stability.